EverSource Wealth Advisors’s Akebia Therapeutics AKBA Stock Holding History

EverSource Wealth Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.28K	Buy	1,997 +1,470	+279%	+$1.75K	﹤0.01%	3676
2026 Q1	$732	Buy	+527	New	+$724	﹤0.01%	3960
2025 Q4	–	Sell	-469	Closed	-$1.28K	–	4274
2025 Q3	$1.28K	Sell	469 -64	-12%	-$213	﹤0.01%	3683
2025 Q2	$1.94K	Buy	533 +290	+119%	+$797	﹤0.01%	3519
2025 Q1	$467	Buy	243 +229	+1,636%	+$467	﹤0.01%	3480
2024 Q4	$27	Buy	+14	New	+$24	﹤0.01%	3691
2023 Q1	–	Sell	-1,250	Closed	-$721	–	2378
2022 Q4	$721	Hold	1,250	–	–	﹤0.01%	2156
2022 Q3	$0	Hold	1,250	–	–	﹤0.01%	1962
2022 Q2	$0	Hold	1,250	–	–	﹤0.01%	1702
2022 Q1	$1K	Hold	1,250	–	–	﹤0.01%	1621
2021 Q4	$3K	Buy	+1,250	New	+$3.41K	﹤0.01%	1388

Other funds holding AKBA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EverSource Wealth Advisors's AKBA Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Akebia Therapeutics (AKBA) stake by 279% in Q2 2026, buying an estimated $1.75K and bringing the position to 1,997 shares worth $2.28K. The position accounts for ﹤0.01% of the portfolio, ranked #3676.

EverSource Wealth Advisors first reported a position in AKBA in Q4 2021 and has held it in 11 quarters since. The position peaked at $3K in Q4 2021. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

EverSource Wealth Advisors held 1,997 shares of Akebia Therapeutics worth $2.28K as of Q2 2026.
EverSource Wealth Advisors bought 1,470 Akebia Therapeutics shares in Q2 2026, an estimated $1.75K.
Akebia Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3676 holding.
EverSource Wealth Advisors first reported a position in Akebia Therapeutics in Q4 2021 and has held it in 11 quarters since.
EverSource Wealth Advisors's Akebia Therapeutics position peaked at $3K in Q4 2021.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.